anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The reproductive efficiency and milk yield of cows are crucial factors in a dairy farm's profitability. However, abortions can have a negative impact on these factors. While the morbidity of abortion has been estimated in many countries, information on the burden on dairy cattle in tropical conditions is limited, and Costa Rica is a good example. This study aims to assess the incidence and recurrence of bovine abortion in dairy cattle from Costa Rica. The study analysed the morbidity of abortion in Costa Rican dairy herds between 2010 and 2022. The incidence rate (IR) and the recurrence rate (ReR) were calculated per 100 cow-months at risk using data from the Veterinary Automated Management and Production Control Programme (VAMPP). The dataset comprised 1032,457 lactations from 330,265 cows in 1134 specialized dairy herds. Abortions were classified either as early foetal mortality (EFM) or late foetal mortality (LFM). Rates were estimated based on cow breed, lactation number, and ecological zone to which the farm belongs. The IR of general abortion, EFM, and LFM cases were 0.98, 0.41, and 0.57 per 100 cow-months at risk, respectively. No statistically significant differences were found in the IR between cow breed, lactation number, and ecological zone, nor for the trend of abortions over calving years. The first ReR (for cows that had one previous abortion during the lactation) was 0.95, and the second ReR (for cows that had two previous abortions during the lactation) was 1.41 per 100 cow-months at risk. These results suggest that bovine abortions are an important ongoing problem in dairy farms in Costa Rica with potentially detrimental effects on the reproductive and productive performance of cows and may be representative of other specialized tropical dairy systems in Latin America.
PURPOSE:To enable filling and solidification of powdery solid cosmetic without causing scattering of powder, by supplying a powdery solid cosmetic to a cavity of a filling mold using air stream, solidifying the powder to a semi-solid state by the pressure of the air stream, filling in a container and solidifying by pressing with a press. CONSTITUTION:A core of a pallet 1 is transferred by intermittent motion of a conveyor 3 to the position of a cylinder apparatus B for forcing down the core and is forced down by the cylinder apparatus B. An inner dish container 2 is fitted to the formed hollow part. A powdery solid cosmetic is carried on an air stream and supplied to the filling mold 33 of a filling machine 8. Air is released through the exhaustion path 37 of a closing member 36 made of a sintered metal and the cosmetic in the filling mold 33 is solidified to a semi- solid state by the pressure of the remaining compressed air. The semi-solid cosmetic is transferred with a piston 35 to an inner dish 2 transferred below the filling machine 8 and is pressed with a press 9. The core is pushed up with a cylinder apparatus D for pushing up the core and the inner dish container 2 is pushed out of the hollow part.
In addition to standard of care services at the participant's respective health system, and study specific collection of clinical, PRO, and wearable data, as well as microbiome specimens, individuals randomized to the intervention group will receive immediate enrollment to a 6-month digital health coaching program followed by 6 months monitoring via PRO, wearable, and clinical data collection. They will collect fecal microbiome samples at baseline (study enrollment) and month 6 following enrollment.
The system (1) to give a topical application of an active substance uses a textile garment (2). The carrier (3) containing the active substance is a patch fitted to the garment (2) fabric at the required location. The garment (2) is a jacket, joint warmer, neck warmer, hand covering, foot cloth, vest or a cloth. The carrier (3) for the active substance is in at least two layers. One layer carries the active substance, and the other layer is an adhesive cladding. The carrier layer is of a material which does not react with pharmaceuticals. The adhesive does not react with pharmaceuticals. An intermediate layer can be inserted between the carrier layer for the pharmaceutical substance, and the adhesive layer.
Recently, particulate matter (PM) has been shown to exacerbate atopic dermatitis (AD) by inducing an inflammatory response. Meanwhile, several studies revealed that exosomes derived from adipose tissue-derived mesenchymal stem cells promote wound healing and alleviate inflammation via their regenerative and immunomodulatory capacities. Our study aimed to investigate the effects of human adipose tissue-derived mesenchymal stem cell-derived (ASC)-exosomes in PM-induced AD. An AD-like triple-cell model was established by treating human keratinocytes, dermal fibroblasts, and mast cells with polyinosinic:polycytidylic acid (Poly I:C) and interleukin 1 alpha (IL-1α). The effects of PM and ASC-exosomes on the expression of pro-inflammatory cytokines and skin barrier proteins were examined using quantitative real-time polymerase chain reaction, western blotting, and immunofluorescence. PM increased pro-inflammatory cytokines (IL-6, IL-1β, and IL-1α) and decreased the anti-inflammatory cytokine IL-10, while the mRNA expression of skin barrier proteins (loricrin and filaggrin) decreased. However, when the cells were treated with ASC-exosomes, the PM-induced effects on pro-inflammatory cytokines and skin barrier proteins were reversed. Our results confirmed that PM-induced inflammation and skin barrier damage were alleviated by ASC-exosomes in our AD-like triple-cell model. These data suggest that ASC-exosomes can serve as a therapeutic agent for PM-exacerbated AD.
Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS). Guideline recommendations on the use of dual antiplatelet therapy (DAPT) have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for patients who have an ACS with or without ST-segment elevation. These recommendations are primarily based on large, randomized, Phase III clinical trials. However, few East Asian patients (or those of East Asian descent) have been included in these trials to assess the use of these drugs. In addition, a growing body of data supported that East Asian might have different adverse event profiles (thrombophilia and bleeding) and "therapeutic window" compared with white subjects. Furthermore, "East Asian paradox" phenomenon has been described that East Asian patients have a higher prevalence of platelet reactivity during DAPT, but an ischaemic event rate following PCI or ACS is similar or even lower than white patients. Therefore, the antiplatelet treatment strategy that is most appropriate for East Asian patients is increasingly urgent. In Korea and Japan, it has been reported that low doses of ticagrelor had a more potent inhibition of platelet aggregation (IPA) than clopidogrel (75 mg once daily) in healthy subjects and patients with stable coronary artery disease, respectively. But it is still not clear whether a low dose of ticagrelor is superior to clopidogrel in a large population of Chinese ACS patients. A recent study on pharmacokinetics and tolerability of ticagrelor has found that maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of ticagrelor (90 mg twice daily) and its active metabolite (AR-C124910XX) tended to be approximately 40% higher in healthy Chinese volunteers compared with Caucasian subjects. This data also suggested that a low dose of ticagrelor might be more appropriate for Chinese ACS patients. In view of a large diurnal variation with a single daily dose, a lower dose twice daily may be a better choice for Chinese patients. Therefore, we performed the current study to observe the different effects of low-dose ticagrelor (45 mg twice daily), conventional-dose ticagrelor (90 mg twice daily) and clopidogrel (75mg once daily) on high platelet reactivity (HPR) and IPA, and investigated the safety and efficacy of low-dose ticagrelor further in Chinese patients with non-ST-elevation ACS (NSTE-ACS).
PROBLEM TO BE SOLVED: To obtain powder trehalose containing amorphous anhydrous trehalose and/or anhydrous crystal trehalose, useful as a strong and safe dehydrating agent, capable of readily providing a high-quality anhydrous food having a good flavor, a high-activity stable anhydrous medicine, etc., by drying a trehalose hydrous substance. SOLUTION: This method for producing powder trehalose comprises drying a trehalose hydrous substance. To be concrete, for example, trehalose hydrous crystal is dried under normal pressure or in vacuum at 100-160 deg.C and ground to give the objective powder. When a high-purity aqueous solution of trehalose is used, for example, powder can be directly obtained from a syrup having 60-80% concentrated by a spray drying method such as a high-pressure nozzle method, etc. The amount of the powder used is preferably 0.01-50 pt.wt. based on 1 pt.wt. of a hydrous article such as a hydrous food, a hydrous medicine, etc.
Ganetespib (STA-9090) 200 mg/m\^2 intravenous infusion once weekly for 3 consecutive weeks followed by one week dose free interval (3 weeks on and 1 week off represent a treatment cycle). Treatment continues until disease progression or unacceptable toxicity.
During the MRI scan, subjects will do a task that requires close concentration. Subjects will be asked to respond quickly to images on the computer screen, during which they will hear distracting noises. The subject will be able to remove the distraction in order to complete the task. During some sub-study sessions, subjects will start with no money ($0) and may be able to earn up to $40 if they do not remove the distraction. At other sub-study sessions, subjects will start with $40 and may lose between 25 to $1 each time they remove the distraction. Subjects cannot lose more than $40 in these sessions. Compensation for this sub-study is up to $40 per session, depending on their performance.
Background: Manual therapy (MT) has been widely used in China to treat local tissue inflammation for a long time. However, there is a lack of scientific evidence for using MT in anti-inflammatory therapy, and its anti-inflammatory mechanism needs further clarification. Methods: We utilized MT to treat cardiotoxin (CTX) injury-induced skeletal muscle inflammation in C57BL6/J mice. We analyzed the underlying mechanism by integrating single-cell RNA sequencing (scRNA-seq) with molecular techniques. Hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining were used to assess skeletal muscle inflammation and muscle fiber cross-sectional area (CSA). scRNA-seq, immunofluorescence, and western blot were performed to determine cellular and molecular outcome changes. Results: Compared with CTX injury-induced skeletal muscle inflammatory mice, MT intervention significantly reduced proinflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (TNF-α) expression levels; scRNA-seq detected that neutrophil numbers and activity were maximum proportions increased in injured skeletal muscle among macrophage, T cells, B cells, endothelial cells, fast muscle cells, fibroblasts, and skeletal muscle satellite cells; and S100A9 gene expression was supreme in neutrophils. However, after treatment with MT, S100A9 protein expression and the numbers and activity of Ly6g+/Mpo+ neutrophils were significantly inhibited, thus reducing the inflammatory cytokine levels and exerting an anti-inflammatory effect by early clearing neutrophils. Conclusion: MT can mitigate localized inflammation induced by injured skeletal muscle, achieved by decreasing S100A9 protein expression and clearing neutrophils in mice, which may help advance therapeutic strategies for skeletal muscle localized inflammation.
PURPOSE: To prepare an agent for suppressing and treating atherosclerosis having cholesterol biosynthesis inhibiting activities and hypercholesterolemia inhibiting activities by including bisphosphonate squalene synthase inhibitor. CONSTITUTION: This agent for suppressing and treating atherosclerosis includes bisphosphonate compound of the formula (R<1> to R<4> are each H, an alkyl, an aryl, ammonium, etc.; at least one of R<5> and R<6> is hydroxycarbylheterocycle, etc.), e.g. tetramethyl 1-(p-chlorophenyl)methane-1-hydroxy-1,1-diphosphonate. The compound has a methylene bonded to both phosphonate, and further at least one lipophilic group bonded to the methylene group. The agent is used for increasing a high density lipoprotein cholesterol level and is also useful for inhibition of gallstone formation, tumor treatment, pressure decrease, treatment of glycosuria, etc.
Stop Natazia if an arterial or venous thrombotic event (VTE) occurs. 

The use of COCs increases the risk of venous thromboembolism. However, pregnancy increases the risk of venous thromboembolism as much or more than the use of COCs. The risk of VTE in women using COCs has been estimated to be 3 to 9 per 10,000 woman-years. The risk of VTE is highest during the first year of use. Data from a large, prospective cohort safety study of various COCs suggest that this increased risk, as compared to that in non-COC users, is greatest during the first 6 months of COC use. Data from this safety study indicate that the greatest risk of VTE is present after initially starting a COC or restarting (following a 4 week or greater pill-free interval) the same or a different COC.

Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. 

The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued. 

If feasible, stop Natazia at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism. 

Start Natazia no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week. 

COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (>35 years of age), hypertensive women who also smoke. COCs also increase the risk for stroke in women with other underlying risk factors. 

Oral contraceptives must be used with caution in women with cardiovascular disease risk factors. 

Stop Natazia if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. [See Adverse Reactions (6).]
PURPOSE: An external use skin composition containing honey and bee venom is provided to ensure excellent moisturizing, antibacterial, and cell regeneration efficiency. CONSTITUTION: An external use skin composition for wound healing contains honey and bee venom as an active ingredient. The fructose rate of the honey is 10-30 wt%. The honey is contained in 0.001-99 wt% based on total weight of the composition. The external use skin composition is used in the form of a cream, gel, dressing agent, patch, spray, ointment, liniment, powder, lotion, plaster, or cataplasma agent. The daily dose of the active ingredient is 0.00001~100 mg/kg.
These survivors will be asked to self-monitor moderate-to-vigorous physical activity (MVPA) participation by wearing the Fitbit Inspire 2 each day over 12 weeks. This group will not receive the MVPA counseling from the coaches.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to preparing the novel pharmaceutical medicinal form for oral administration. This form has core material including inhibitor or protonic pump, one or some alkaline reactive compounds and, optionally, pharmaceutically acceptable filling agents and water-soluble partition layer and enterosoluble cover layer. Indicated core material is alkaline reactive compound and indicated partition layer is formed in situ as water-soluble salt in the process of application of enterosoluble cover on alkaline reactive material of core as the result of reaction between polymeric enterosoluble cover (or covers) and alkaline reactive compound (or compounds). Invention relates to also method of inhibition of acid secretion by administration of indicated medicinal form containing two functionally different layers prepared for a single stage. EFFECT: new effective method of inhibition of acid secretion, simplified technological process. 17 cl, 1 dwg, 8 tbl, 7 ex
This study aimed to investigate both chronic health conditions and the utilization of patient portals, focusing particularly on caregivers responsible for individuals with Alzheimer's disease and related dementias (ADRD). Data from the Health Information National Trends Survey 2018-2020 were analyzed, involving a sample of 304 family and unpaid caregivers of individuals with ADRD. Among caregivers of individuals with ADRD, 77.6% had at least one chronic disease. A significant proportion (46.6%) of ADRD caregivers had never accessed their patient portals. The limited utilization of patient portals among caregivers responsible for individuals with ADRD, particularly those with lower education, advanced age, and few chronic conditions, becomes apparent due to challenges associated with digital literacy and discomfort with computers. Recognizing the crucial role caregivers play for individuals with ADRD and their health risks, there's a need for tailored training to enhance their health management skills and caregiving capabilities.
This was initially a phase I/II, open-label, non-randomized study using an investigational new drug, TL 32711, in patients with acute myelogenous leukemia. This study targeted subjects 60 years of age and older (with non-M3 AML who have relapsed or refractory disease after standard therapy or who are newly diagnosed and not candidates for standard induction therapy) and subjects 18-59 (relapsed or refractory after failing 3 prior lines of therapy). Subjects would receive the study drug in 4 weeks dosing periods via one of three different treatment schedules (once weekly, twice weekly or three times weekly dosing). They would receive treatment for up to 6 cycles, however treatment may have been extended at the discretion of the study doctor if felt to be in the best interest of the subject. Up to 46 subjects were to be enrolled on this study at the University of Pennsylvania, depending on the number of subjects needed in the Phase I component in order to determine the MTD. The primary objective of the Phase 1 component was to determine the safety and tolerability of TL32711, and the MTD in this patient population. The primary objective of the Phase 2 portion of this study was to further define the safety and tolerability, and provide preliminary efficacy data, however, the Phase II portion was never initiated.
All participant will exam brachial artery endothelium-dependent flow-mediated dilatation (FMD). After then, pneumatic cuff wiil be inflated to 200 mmHg for 15 minutes to induce brachial artery ischemia. At the end of ischemia, 15 minutes of reperfusion was performed to induce reperfusion injury. After ischemia-reperfusion (IR) injury, brachial artery FMD will be measured again. After randomization, sitagliptin group will be treated by single dose of sitagliptin (Januvia) 50mg. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
The invention relates to a preparation method of a multifunctional medicine carrier integrating magnetism, fluorescence and thermosensitivity. The carrier structure uses chitosan microspheres grafted by poly(N-isopropyl acrylamide) as a main body internally crosslinked with porous silicon nano particles. The nano particles encapsulate superparamagnetic nano particles and inorganic quantum dots, so that a composite microsphere carrier which takes porous silicon nano particles loading magnetic particles and quantum dots as a core and chitosan grafted by poly(N-isopropyl acrylamide) as a shell is formed. The carrier can load the anti-cancer medicine in a shell network of a polymer so as to sequentially release the medicine at special temperatures. Compared with the prior art, the medicine carrier provided by the invention has hydrophilcity and biocompatibility, so that the anti-cancer medicine is controllably encapsulated and released. Meanwhile, the medicine carrier has magnetic targeting fluorescent tracing functions, and has important research and application values in associated fields of biology, medicines and materials such as sustained-release materials, medicine carriers, catalyst carriers and separating media.
Participants will receive binimetinib by mouth two times a day, every day during each cycle. Each cycle will last for 21 days. Participants will receive belinostat by intravenous infusion on days 1 through 5 of each cycle.
Cancer remains a formidable challenge, continually revealing its intricate nature and demanding novel treatment approaches. Within this intricate landscape, the tumor microenvironment and its dynamic components have gained prominence, particularly macrophages that can adopt diverse polarization states, exerting a profound influence on cancer progression. Recent revelations have spotlighted lactic acid as a pivotal player in this complex interplay. This review systematically explores lactic acid's multifaceted role in macrophage polarization, focusing on its implications in carcinogenesis. We commence by cultivating a comprehensive understanding of the tumor microenvironment and the pivotal roles played by macrophages. The dynamic landscape of macrophage polarization, typified by M1 and M2 phenotypes, is dissected to reveal its substantial impact on tumor progression. Lactic acid, a metabolic byproduct, emerges as a key protagonist, and we meticulously unravel the mechanisms underpinning its generation within cancer cells, shedding light on its intimate association with glycolysis and its transformative effects on the tumor microenvironment. Furthermore, we decipher the intricate molecular framework that underlies lactic acid's pivotal role in facilitating macrophage polarization. Our review underscores lactic acid's dual role in carcinogenesis, orchestrating tumor growth and immune modulation within the tumor microenvironment, thereby profoundly influencing the balance between pro-tumor and anti-tumor immune responses. This duality highlights the therapeutic potential of selectively manipulating lactic acid metabolism for cancer treatment. Exploring strategies to inhibit lactic acid production by tumor cells, novel approaches to impede lactic acid transport in the tumor microenvironment, and the burgeoning field of immunotherapeutic cancer therapies utilizing lactic acid-induced macrophage polarization form the core of our investigation.